The Hematologic Malignancy DNA Sequencing Panels are designed to identify clinically relevant DNA mutations for the diagnosis, prognosis, and treatment of patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, and lymphoma. The appropriate panel should be selected. Single gene analysis and custom panels are also available. TruSight MiSeq high throughput targeted sequencing technology is used to identify mutations within the following 44 genes: Comprehensive Hematologic Malignancy Panel includes: ABL1, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CEBPA, CORL1, CSF3R, CUX1, DNMT3A, ETV6/TEL, EZH2, FBXW7, FLT3, GATA1, GATA2, IDH1, IDH2, IKZF1, JAK2, JAK3, KIT, KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2 AML Panel includes: ABL1, ASXL1, BCOR, BCORL1, BRAF, CEBPA, DNMT3A, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, NPM1, NRAS, PHF6, RAD21, RUNX1, SETBP1, SRSF2, STAG2, TET2, TP53, WT1 MDS, MPS, OR MDS/MPN Panel includes: ABL1, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CSF3R, CUX1, DNMT3A, ETV6/TEL, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, RAD21, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, ZRSR2 ALL Panel includes: ABL1, BRAF, DNMT3A, ETV6/TEL, FBXW7, FLT3, IKZF1, JAK2, JAK3, KIT KRAS, NOTCH1, NRAS, PTEN, PTPN11, RUNX1, TP53 Lymphoma Panel includes: BRAF, DNMT3A, EZH2, FBXW7, IDH1, IDH2, JAK2, JAK3, KIT, KRAS, MYD88, NOTCH1, NRAS, SF3B1, TET2, TP53 Acute Leukemia NOS Panel includes: ABL1, ASXL1, BCOR, BCORL1, BRAF, CEBPA, DNMT3A, ETV6/TEL, FBXW7, FLT3, GATA1, GATA2, IDH1, IDH2, IKZF1, JAK2, JAK3, KIT, KRAS, NOTCH1, NPM1, NRAS, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SRSF2, STAG2, TET2, TP53, WT1
Performing Laboratory / Facility
UCLA Medical Center Clinical Laboratory (CHS)
Performing Section
Molecular Pathology
Availability
Monday through Friday, 0700-1700
Turnaround Time
14 days from receipt of specimen in performing lab
Methodology
The Hematologic Malignancy DNA Sequencing Panels are a next-generation sequencing (NGS) test performed on DNA extracted from blood or bone marrow aspirate. It is capable of identifying DNA mutations in the aforementioned 44 genes. Target sequences are enriched using the TruSight Myeloid Sequencing Panel (Illumina, Inc.) and analyzed on the MiSeqDx Desktop Sequencer (Illumina Inc.). Targeted genes generally do not involve sequencing of the entire coding region, and only selected exons within each gene which are known to contain clinically significant somatic mutations are typically targeted. Alternate methodologies (polymerase chain reaction followed by amplicon sizing via capillary electrophoresis or dideoxy DNA sequencing) may be used to detect specific DNA mutations in the FLT3, CALR, and CEBPA genes when definitive results for these genes cannot be determined via NGS. Only mutations which are thought to be clinically significant based on existing knowledge will be reported.
This test has been validated by the UCLA Molecular Diagnostics Laboratories. This assay can detect a mutant allele present in approximately 5% to 10% of the total DNA content. Preparation of DNA is dependent on the specimen provided. A negative (no mutation detected) result does not preclude the presence of clinically relevant DNA mutations since results depend on a multitude of factors, including but not limited to, mutant allele frequency, specimen integrity, presence of inhibitors, and/or interfering polymorphisms, availability of sufficient high-quality DNA, the genomic location of the mutations, and existing knowledge available at the time of testing regarding the clinical impact of the mutations.
The Hematologic Malignancy DNA Sequencing Panels are designed to identify clinically relevant DNA mutations for the diagnosis, prognosis, and treatment of patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, and lymphoma. The appropriate panel should be selected. Single gene analysis and custom panels are also available. TruSight MiSeq high throughput targeted sequencing technology is used to identify mutations within the following 44 genes: Comprehensive Hematologic Malignancy Panel includes: ABL1, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CEBPA, CORL1, CSF3R, CUX1, DNMT3A, ETV6/TEL, EZH2, FBXW7, FLT3, GATA1, GATA2, IDH1, IDH2, IKZF1, JAK2, JAK3, KIT, KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2 AML Panel includes: ABL1, ASXL1, BCOR, BCORL1, BRAF, CEBPA, DNMT3A, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, NPM1, NRAS, PHF6, RAD21, RUNX1, SETBP1, SRSF2, STAG2, TET2, TP53, WT1 MDS, MPS, OR MDS/MPN Panel includes: ABL1, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CSF3R, CUX1, DNMT3A, ETV6/TEL, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, RAD21, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, ZRSR2 ALL Panel includes: ABL1, BRAF, DNMT3A, ETV6/TEL, FBXW7, FLT3, IKZF1, JAK2, JAK3, KIT KRAS, NOTCH1, NRAS, PTEN, PTPN11, RUNX1, TP53 Lymphoma Panel includes: BRAF, DNMT3A, EZH2, FBXW7, IDH1, IDH2, JAK2, JAK3, KIT, KRAS, MYD88, NOTCH1, NRAS, SF3B1, TET2, TP53 Acute Leukemia NOS Panel includes: ABL1, ASXL1, BCOR, BCORL1, BRAF, CEBPA, DNMT3A, ETV6/TEL, FBXW7, FLT3, GATA1, GATA2, IDH1, IDH2, IKZF1, JAK2, JAK3, KIT, KRAS, NOTCH1, NPM1, NRAS, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SRSF2, STAG2, TET2, TP53, WT1
Performing Laboratory / Facility
UCLA Medical Center Clinical Laboratory (CHS)
Performing Section
Molecular Pathology
Availability
Monday through Friday, 0700-1700
Turnaround Time
14 days from receipt of specimen in performing lab
Methodology
The Hematologic Malignancy DNA Sequencing Panels are a next-generation sequencing (NGS) test performed on DNA extracted from blood or bone marrow aspirate. It is capable of identifying DNA mutations in the aforementioned 44 genes. Target sequences are enriched using the TruSight Myeloid Sequencing Panel (Illumina, Inc.) and analyzed on the MiSeqDx Desktop Sequencer (Illumina Inc.). Targeted genes generally do not involve sequencing of the entire coding region, and only selected exons within each gene which are known to contain clinically significant somatic mutations are typically targeted. Alternate methodologies (polymerase chain reaction followed by amplicon sizing via capillary electrophoresis or dideoxy DNA sequencing) may be used to detect specific DNA mutations in the FLT3, CALR, and CEBPA genes when definitive results for these genes cannot be determined via NGS. Only mutations which are thought to be clinically significant based on existing knowledge will be reported.
This test has been validated by the UCLA Molecular Diagnostics Laboratories. This assay can detect a mutant allele present in approximately 5% to 10% of the total DNA content. Preparation of DNA is dependent on the specimen provided. A negative (no mutation detected) result does not preclude the presence of clinically relevant DNA mutations since results depend on a multitude of factors, including but not limited to, mutant allele frequency, specimen integrity, presence of inhibitors, and/or interfering polymorphisms, availability of sufficient high-quality DNA, the genomic location of the mutations, and existing knowledge available at the time of testing regarding the clinical impact of the mutations.
